Gyroscope Therapeutics focuses on innovative gene therapies aimed at treating eye diseases, particularly those that lead to vision loss. Their proprietary technology platform utilizes adeno-associated virus (AAV) vectors to deliver therapeutic genes directly to the retinal cells. This approach is designed to address the underlying genetic causes of diseases such as geographic atrophy and other inherited retinal disorders, potentially restoring vision or halting disease progression. By leveraging the precision of gene therapy, Gyroscope aims to provide long-lasting solutions for patients suffering from these debilitating conditions.

In addition to their gene therapy platform, Gyroscope Therapeutics emphasizes the importance of robust clinical development and regulatory strategies to ensure the safety and efficacy of their treatments. The company is committed to conducting comprehensive clinical trials that not only evaluate the therapeutic impact of their products but also gather valuable data on patient outcomes. This focus on patient-centric research underscores Gyroscope's mission to transform the treatment landscape for retinal diseases, ultimately improving the quality of life for individuals affected by vision loss.

United Kingdom

Discovering and developing innovative medicines to preserve people’s sight and fight the devastating impact of blindness around the world.

Gyroscope Therapeutics

Company Details